Format

Send to

Choose Destination
Open Forum Infect Dis. 2016 Jul 13;3(3):ofw152. eCollection 2016 Sep.

Penicillin Use in Meningococcal Disease Management: Active Bacterial Core Surveillance Sites, 2009.

Author information

1
Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases , Centers for Disease Control and Prevention , Atlanta, Georgia.
2
Department of International Health , Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland.
3
Department of Medicine , Emory University School of Medicine and the Atlanta VA Medical Center , Georgia.
4
Minnesota Department of Health, St. Paul.
5
Colorado Department of Public Health and Environment, Denver.
6
New Mexico Department of Health, Sante Fe.
7
Connecticut Department of Public Health, Hartford.
8
School of Public Health , University of California , Berkley.
9
Department of Preventive Medicine , Vanderbilt University School of Medicine , Nashville, Tennessee.
10
Oregon Department of Human Services, Portland.
11
New York State Department of Health, Albany.

Abstract

In 2009, in the Active Bacterial Core surveillance sites, penicillin was not commonly used to treat meningococcal disease. This is likely because of inconsistent availability of antimicrobial susceptibility testing and ease of use of third-generation cephalosporins. Consideration of current practices may inform future meningococcal disease management guidelines.

KEYWORDS:

Neisseria meningitidis; antimicrobial resistance; meningitis; meningococcal disease

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center